Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion

Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Wecker, Bastian Grundel, Milena Grundel, Marie-Christine Bründer, Simon Trick, Clemens Lange, Daniel Böhringer, Hansjürgen Agostini, Andreas Stahl
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a618870fd8174289bae2b33e07f100e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a618870fd8174289bae2b33e07f100e2
record_format	dspace
spelling	oai:doaj.org-article:a618870fd8174289bae2b33e07f100e22021-12-02T14:30:51ZReal-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion10.1038/s41598-021-87467-62045-2322https://doaj.org/article/a618870fd8174289bae2b33e07f100e22021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87467-6https://doaj.org/toc/2045-2322Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.Thomas WeckerBastian GrundelMilena GrundelMarie-Christine BründerSimon TrickClemens LangeDaniel BöhringerHansjürgen AgostiniAndreas StahlNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Thomas Wecker Bastian Grundel Milena Grundel Marie-Christine Bründer Simon Trick Clemens Lange Daniel Böhringer Hansjürgen Agostini Andreas Stahl Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
description	Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.
format	article
author	Thomas Wecker Bastian Grundel Milena Grundel Marie-Christine Bründer Simon Trick Clemens Lange Daniel Böhringer Hansjürgen Agostini Andreas Stahl
author_facet	Thomas Wecker Bastian Grundel Milena Grundel Marie-Christine Bründer Simon Trick Clemens Lange Daniel Böhringer Hansjürgen Agostini Andreas Stahl
author_sort	Thomas Wecker
title	Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
title_short	Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
title_full	Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
title_fullStr	Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
title_full_unstemmed	Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
title_sort	real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a618870fd8174289bae2b33e07f100e2
work_keys_str_mv	AT thomaswecker reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT bastiangrundel reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT milenagrundel reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT mariechristinebrunder reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT simontrick reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT clemenslange reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT danielbohringer reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT hansjurgenagostini reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion AT andreasstahl reallifemediumtermfollowupdataforintravitrealdexamethasoneimplantinretinalveinocclusion
_version_	1718391211180425216

Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion

Ejemplares similares